Quantcast

Latest Insulin glargine Stories

2014-05-12 08:32:58

Lilly expects U.S. and European regulatory submissions by Q1 2015 INDIANAPOLIS, May 12, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive top-line results of three completed Phase III clinical trials in patients with type 2 diabetes for basal insulin peglispro (BIL), which is being studied as a once-daily treatment for both type 1 and type 2 diabetes. The primary efficacy endpoint of non-inferior reduction in hemoglobin A1c (HbA1c) compared to insulin...

2014-03-24 23:24:35

MarketOptimizer.org offers “PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update” to its store. Dallas, Texas (PRWEB) March 24, 2014 This report focuses on type 2 diabetes pharmaceuticals in seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) and three emerging markets (China, India and Brazil). These 10 markets will be referred to as the global market. The global type 2 diabetes pharmaceutical markets in the 2012...

2014-03-25 00:23:22

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/kz2b9w/investigation) has announced the addition of the "Investigation Report on China Insulin Glargine Market, 2009-2018" [http://www.researchandmarkets.com/research/kz2b9w/investigation ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) With the improvement of people's living standard and changing of...

2014-03-06 23:28:29

Diabetic Patients Can Obtain Discounts of 10%-75% on Lantus and Metformin San Antonio, TX (PRWEB) March 06, 2014 As of 2013, diabetes affected nearly 26 million people—more than 8% of the U.S. population. This number includes those diagnosed with "pre-diabetes" as well as those who manage their condition with diet and exercise, oral medication, or by injecting insulin. Diabetes is a serious condition, and improper management can lead to blindness, limb atrophy and...

2014-02-28 23:01:12

ChinaMarketResearchReports.com adds Latest Report on “Investigation Report on China Insulin Glargine Market, 2009-2018” to its store. Dallas, TX (PRWEB) March 01, 2014 Description With the improvement of people's living standard and changing of lifestyles, as well as deepening of the aging of society, prevalence rate of diabetes keeps rising, making it the third most threatening chronic disease to human health after tumor and cardiovascular disease. Its risk to disable or kill has...

2014-02-25 08:31:50

Once-Weekly Dulaglutide Hits Primary Endpoint in Sixth Consecutive AWARD Trial INDIANAPOLIS, Feb. 25, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive top-line results of the sixth AWARD (Assessment of Weekly AdministRation of LY2189265 in Diabetes) trial for once-weekly dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a treatment for type 2 diabetes. In the AWARD-6 study, once-weekly...

2014-02-19 23:24:56

Taiwanese author says his research should relieve concern among diabetics that insulin might raise their cancer risk. Raleigh, NC (PRWEB) February 19, 2014 Cancer Monthly is reporting on a recently-published meta-analysis of diabetes patients that appears to show no increased risk of bladder cancer as a result of using human insulin. The large-scale study analyzed the health insurance reimbursement databases of 785,234 type 2 diabetes patients from 1996 to 2009. In 2009, the entire...

2014-01-31 12:25:16

INDIANAPOLIS, Jan. 31, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has provided the following statement regarding a lawsuit filed by Sanofi in the United States District Court for the District of Delaware alleging patent infringement with respect to LY2963016, a new insulin glargine product for which Lilly is currently seeking approval from the U.S. Food and Drug Administration (FDA). "Lilly respects the intellectual property of others and does not believe the...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related